Anti-ARHGAP26 antibody

  • Description

  • Application Data


Antibody raised against Rho GTPase activating protein 26 (ARHGAP26), a negative regulator of G proteins RhoA and Cdc42.  ARHGAP26 is a molecular switch regulating tumour cells.

See full description

Application Data

Catalogue number crb2005668
Antibody Anti-ARHGAP26 antibody
Antigen Peptide KLH conjugated synthetic peptide crb1200877e
Protein ID Q9UNA1 ARHGAP26
Aliases Rho GTPase-activating protein 26, GTPase regulator associated with focal adhesion kinase, Oligophrenin-1-like protein, Rho-type GTPase-activating protein 26
Host Species Rabbit
Antibody Type Polyclonal
Concentration 2.0mg/ml Glycine (R2G), 1.0mg/ml Glycine (R1G)
Target ARHGAP26
Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.
Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.

Katoh, M. and Katoh, M. (2004). Characterization of human ARHGAP10 gene in silico. International Journal of Oncology, 25(4), pp.1201–1207.

Zhang, L., et al. (2021). The role of GTPase-activating protein ARHGAP26 in human cancers. Molecular and Cellular Biochemistry, 477(1), pp.319–326.

Material Safety Data Sheet (MSDS)

Rho GTPase Activating Protein 26 (ARHGAP26) is a rho family negative regulator, used to convert G proteins RhoA and Cdc42 into their inactive forms. It can exist in multiple forms, with ARHGAP10 being a paralog gene of particular significance. As a type of GTPase-activating protein, ARHGAP26 has the capacity to enhance hydrolysis of GTPases, converting them from an active to an inactive form, therefore inhibiting signal transduction.

This type of protein plays an important role in regulation of the behaviour of cancer cells, this occurs through ARHGAP26 being a GTPase-activating protein, meaning it can inhibit Rho-GTPases by promoting their hydrolytic ability. ARHGAP26 can also have an affect on tumorigenesis and tumour progression, by forming abnormal fusion genes, tumour development and progression can be both slowed down or sped up by ARHGAP. Understanding the molecular mechanisms of ARHGAP26 could help unearth its potential clinical value in cancer treatments.

Anti-ARHGAP26 antibody

Cat No.Pack SizePriceQty.
Bulk Quote